Anti-angiogenic drug discovery: lessons from the past and thoughts for the future

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Anti-angiogenic agents, like bevacizumab, represent a novel cancer treatment modality.
• Numerous clinical trials investigate angiogenesis inhibitors targeting the tumor vascularization pathway.
• Current anti-angiogenic therapies offer marginal benefits and significant side effects in unselected patient groups.

Purpose of the Study:

• To review the clinical application and lessons learned from bevacizumab and other VEGF pathway inhibitors.
• To synthesize findings from pre-clinical and clinical studies on angiogenesis inhibitors in cancer treatment.

Main Methods:

• Comprehensive literature review of anti-VEGF agents and angiogenesis inhibitors.
• Analysis of data from pre-clinical and clinical trials in cancer therapy.

Main Results:

• Bevacizumab and similar agents have shown limited efficacy in broad patient populations.
• Significant side effects are associated with current anti-angiogenic therapies.
• The need for improved patient selection and treatment strategies is evident.

Conclusions:

• Future drug design emphasizes targeting multiple pathways (growth factors, HIF, tumor endothelial markers) and combination therapies.
• Further research is crucial for optimizing dosing, scheduling, and combining with radiation/chemotherapy.
• Development of predictive biomarkers and early disease treatment strategies are essential for personalized cancer therapy.